peoplePerson
René Bernards
Cancer geneticist who explained why BRAF inhibitors fail in colorectal cancer, leading to the BEACON combination.
René Bernards' functional genetic screens identified EGFR feedback as the reason BRAF inhibitors fail in colorectal cancer, the rationale behind encorafenib plus cetuximab; he co-founded Agendia and developed MammaPrint.
Role
Senior Group Leader, Netherlands Cancer Institute; Professor, Utrecht University
Institution
Specialisms
Cancer geneticsDrug resistanceFunctional genomics
Profiles
| Title | Journal | Year |
|---|---|---|
| Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR | Nature | 2012 |